Table 5 Sensitivity analysis of the studies that had 12 months data on glycated haemoglobin (changes from baseline to 12 months) with comparison for intervention (Int) and control (contr) groups and the heterogeneity (measured by I 2 ) of the analyses
Analysis number / Outcome | Effect measure | N studies | N participants (Int/contr) | Difference (95%CI) | P-valueA | Heterogeneity (I2) |
|---|---|---|---|---|---|---|
5.1 Non-translated publications | Mean Diff | 10 | 630/630 | -0.52 (-0.75 to -0.28) | 0.000 | 41.0 |
5.2 Number of participants more than median of all studies with 12 months HbA1c data(104 total) | Mean Diff | 6 | 568/576 | -0.67 (-0.86 to -0.48) | 0.000 | 18.4 |
5.3 Studies with any part of results recalculated (HbA1c 12-14 months) | Mean Diff | 6 | 450/438 | -0.54 (-0.78 to -0.31) | 0.000 | 0.0 |
5.4 Study quality (Low risk of bias):glycated haemoglobin 12-14 months | Mean Diff | 2 | 192/187 | -0.42 (-1.00 to 0.17) | 0.163 | 77.4 |
5.5 Study quality (Moderate risk of bias) | Mean Diff | 7 | 428/436 | -0.55 (-0.79 to -0.31) | 0.000 | 29.7 |
5.6 Study quality (High risk of bias) | Mean Diff | 2 | 130/130 | -0.95 (-1.55 to -0.35) | 0.002 | 0.0 |
5.7 Study quality (Low & Moderate risk of bias) | Mean Diff | 9 | 620/623 | -0.51 (-0.72 to -0.29) | 0.000 | 41.3 |
5.8 Drop-out rate less than 10 % | Mean Diff | 5 | 444/454 | -0.79 (-0.97 to -0.61) | 0.000 | 0.0 |